Prevalence and implications of the presence of intraocular silicone oil droplets in patients treated with intravitreal injections of anti-VEGF

• Published in: BMC ophthalmology Vol. 22; no. 1; pp. 1 - 319
• Main Authors: García, Sandra Banderas, Garrell-Salat, Xavier, Trejo-Velasco, Fernando, Aragón-Roca, David, Zapata, Miguel Ãngel, García-Arumí, José
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 26-07-2022; BioMed Central; BMC
• Subjects: Anti-VEGF; Bevacizumab; Bubbles; Diabetes; Diabetic retinopathy; Edema; Floaters; Intraocular pressure; Intravitreal injections; Macular degeneration; Macular diseases; Monoclonal antibodies; Patients; Pharmaceuticals; Pharmacy; Silicone droplets; Silicones; Transplants & implants; Variance analysis; Vascular endothelial growth factor; United States > US; San Francisco California; Spain
• ISSN: 1471-2415; 1471-2415
• DOI: 10.1186/s12886-022-02536-2

Background To determine the percentage of patients who have silicone droplets in the vitreous after treatment with different anti-Vascular Endothelial Growth Factor (anti-VEGF) intravitreal injections (IVI) and how symptomatic they are. Methods One hundred fifty-two eyes of 140 patients who had at least received an IVI were recruited for this study. Data collection included the number and type of IVI (aflibercept, ranibizumab and bevacizumab) and the follow-up time. A complete ophthalmologic examination was carried out and patients were classified in four groups according to the amount of silicone droplets found in dilated fundoscopy (nonexistent, scarce, moderate and abundant). Measurement of intraocular pressure (IOP) was also carried out. An interview was conducted to report the presence and intensity of the symptomatology. Results Silicone oil droplets were reported in 109 eyes (71.7%). A positive correlation was found between the number of IVIs received and the quantity of droplets found, especially when aflibercept was used. Posterior vitreous detachment (PVD) was present in 65.8% of the patients, showing a positive correlation with the number of bubbles. Regarding the symptomatology, 60 eyes (39.5%) had floaters and the disturbance was reported to be 4 out of 10. The group with a moderate amount of silicone droplets had the highest percentage of floaters (60%). No statistical differences in the IOP were found between groups, although the group with abundant droplets had a higher mean IOP. Conclusion A high prevalence of silicone droplets in vitreous of patients who undergo IVI treatment was found. It appears to have little impact on symptomatology and rise of IOP. Keywords: Intravitreal injections, Silicone droplets, Anti-VEGF, Floaters, Intraocular pressure, Macular diseases